Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension

  • Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
  • The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
  • Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
  • HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness

Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology. 

The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes the findings may have a potential impact on efforts to treat not only high blood pressure, but other cardiovascular diseases and other ailments in which blood vessel stiffness is believed to play a significant role. 

“Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” Lexaria President John Docherty stated in the news release. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”

Lexaria’s examination of DehydraTECH-CBD’s effects on arterial stiffness follows its initial findings between July (https://cnw.fm/xLbY9) and September (https://cnw.fm/sK5Ak) that hypertensive volunteers using the company’s processed CBD achieved a marked drop in blood pressure relative to generic CBD controls used as a placebo. 

DehydraTECH is an enabling technological solution that helps drug substances bypass the digestion-liver filtering cycle that may reduce their effectiveness. DehydraTECH’s platform works with the body to rapidly process drugs into the blood stream before potentially being filtered out by the liver’s enzyme-generating factory. 

Additional testing by Canada’s premier federally funded research organization, the National Research Council demonstrated DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity (“NME”) and that each drug tested remained stable and did not undergo change in chemical structure.  These findings are strongly supportive of accelerated regulatory filings such as the 505(b)(2) pathway permitted by the Food and Drug Administration and other international regulators, for more rapid market authorizations of prospective DehydraTECH-enabled, repurposed drugs (https://cnw.fm/abv6C). 

Lexaria will follow the HYPER-H21-2 study with two new hypertension studies, HYPER-H21-3 and HYPER-H21-4, a new six-week investigation in which multiple doses of DehydraTECH-CBD are expected to indicate further benefits for treating hypertension and arterial stiffness. 

Arterial stiffness naturally increases with age and is associated with increased mortality from diseases such as diabetes mellitus and kidney disorders, as well as the cardiovascular diseases that are the leading cause of death worldwide (https://cnw.fm/HY08k). Dr. Vernon V S Bonarjee, the head of the cardiology department at Norway’s Stavanger University Hospital, has noted that measuring arterial stiffness may serve as a predictive indicator for determining treatment for cardiovascular disease, even among otherwise asymptomatic individuals, demonstrating the condition’s significance (https://cnw.fm/AWuPQ). 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
905.674.5977 Office

CanadianCannabisWire is part of the InvestorBrandNetwork.


Select A Month

CanadianCannabisWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 905.674.5977